A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Janssen Research & Development, LLC
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)